Given the favorable data for the FAST and FAST-Forward trials, can we consider those ultra-hypofractionated whole breast radiation schemes to be standard of care for early-stage breast cancer?

Answer from: Radiation Oncologist at Community Practice

With respect to FAST (28.5 Gy in 5 fx over 5 weeks), it can be considered based on 10-year data. Local control rates were low in all arms, but in general, I limit this to patients who can't do standard hypofractionated WBI (40/15).FAST-Forward now has 10-year outcomes and can be considered for appro...

Comments

Radiation Oncologist at Varian Medical Systems/Allegheny health network
We do offer for 60 and above low-risk disease who ...

Radiation Oncologist at Lake Huron Medical Center
@Chirag S. Shah - do you think the FAST-Forward st...

Radiation Oncologist at Allegheny Health Network, Pittsburgh
It's a great question, @Simul Parikh. In terms of ...

Answer from: Radiation Oncologist at Academic Institution

While there is only 5-year data, I am starting to use FAST-Forward in selected patients with significant transportation or COVID issues, and in whom I don't expect challenges achieving dose homogeneity with a 3D treatment plan. In the first few we've treated - I have followed weekly after treatment ...

Answer from: Radiation Oncologist at Community Practice

Does P2026, favoring SBRT (?), in freestanding centers vs IMRT/3D, likely have an impact on use?

Please select the option that best describes you:

Given the favorable data for the FAST and FAST-Forward trials, can we consider those ultra-hypofractionated whole breast radiation schemes to be standard of care for early-stage breast cancer?

Related Questions